目的 探讨气滞胃痛颗粒联合铝碳酸镁咀嚼片治疗慢性胃炎的临床疗效。方法 选取2018年1月-2019年11月在郑州新郑国际机场急救中心就诊的130例慢性胃炎患者作为研究对象，按照随机数字表法将130例患者分为对照组和治疗组，每组各有65例。对照组口服铝碳酸镁咀嚼片，1.0 g/次，3次/d。治疗组在对照组基础上口服气滞胃痛颗粒，5 g/次，3次/d。两组患者连续治疗8周。观察两组患者的疗效，比较两组的腹痛消失时间、腹胀消失时间、反酸消失时间，对比两组患者炎症因子[C反应蛋白（CRP）、白细胞介素-17（IL-17）、细胞间黏附分子-1（ICAM-1）]和胃肠激素[胃动素（MTL）、胃泌素（GAS）、生长抑素（SS）]水平。结果 治疗后，治疗组患者的总有效率（95.38%）比对照组高（84.62%），差异有统计学意义（P<0.05）。治疗后，治疗组的腹痛消失时间、腹胀消失时间、反酸消失时间比对照组低，差异具有统计学意义（P<0.05）。治疗后，两组的CRP、IL-17、ICAM-1水平均明显降低（P<0.05）；治疗后治疗组患者的CRP、IL-17、ICAM-1水平低于对照组，差异有统计学意义（P<0.05）。治疗后，两组的MTL、GAS均明显降低，SS明显升高（P<0.05）；治疗后治疗组的MTL、GAS水平比对照组低，SS比对照组高，差异有统计学意义（P<0.05）。结论 气滞胃痛颗粒联合铝碳酸镁咀嚼片治疗慢性胃炎的疗效确切，可减轻患者的临床症状，调节胃肠激素的分泌，降低炎症因子水平，具有一定的临床研究价值。

Objective To explore the clinical effect of Qizhi Weitong Granules combined with Hydrotalcite Chewable Tablets in treatment of chronic gastritis. Methods Patients (130 cases) with chronic gastritis in Zhengzhou Xinzheng International Airport Emergency Center from January 2018 to November 2019 were randomly divided into control and treatment groups, and each group had 65 cases. Patients in the control group were po administered with Hydrotalcite Chewable Tablets, 1.0 g/time, three daily. Patients in the treatment group were po administered with Qizhi Weitong Granules on the basis of the control group, 5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the disappearance time of abdominal pain, abdominal distention and acid regurgitation were compared. The levels of inflammatory factors (CRP, IL-17, and ICAM-1) and gastrointestinal hormones (MTL, gas, and SS) were compared. Results After treatment, the total effective rate of the treatment group (95.38%) was higher than that of the control group (84.62%), and the difference was statistically significant (P<0.05). After the treatment, the disappearance times of abdominal pain, abdominal distention and acid regurgitation in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of CRP, IL-17, and ICAM-1 in two groups were significantly lower (P<0.05). After treatment, the levels of CRP, IL-17, and ICAM-1 in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of MTL and GAS in two groups were significantly decreased, and the levels of SS in two groups were significantly increased (P<0.05). After treatment, the levels of MTL and GAS in the treatment group were lower than those in the control group, and the levels of SS in the treatment group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusion Qizhi Weitong Granules combined with Hydrotalcite Chewable Tablets has clinical curative effect in treatment of chronic gastritis, can reduce the clinical symptoms of patients, regulate the secretion of gastrointestinal hormones, reduce the level of inflammatory factors, which has a certain clinical research value.

R975